Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge communication ... partners of platform upgrades. This webinar series demonstrates ... their quest to leverage web conferencing’s most innovative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... American Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill also fills ... voice in furthering the mission of ASRM. , Dr. ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Nventa Biopharmaceuticals,Corporation (TSX: NVN) today announced financial results for ... and highlighted several,recent product developments and corporate milestones., ... Recent product and corporate highlights:, o ... it will initiate a ...
... Risks of Progression of,Vertebral Fracture in US-Caucasian Women, ... (Amex: ILI ), announced today that Nazneen ... Development, will present new research,findings on the genetics ... the,American Society of Human Genetics, which takes place ...
... LLC, a privately-held,biopharmaceutical company focused on developing novel ... Sindbis viral vector, announced today,that it has appointed ... immediately, to lead the company,s next phase of ... Stonebanks will serve on Cynvec,s Board,of Directors., ...
Cached Biology Technology:Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 2Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 4Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 5Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 6Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 7Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 2Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 3Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... red wormlike insects that nibble on the plant's leaves ... larvae that survive eventually evolve methods to overcome plant ... trying to thwart the insect have identified Hessian fly ... itself from the munching larvae. The researchers report their ...
... target organs or cell types, you need a good ... the target in question could do the trick. , ... tiny capsules require preorganized structures or "molds" to shape ... synthetic or purification procedure. Korean researchers led by Kimoon ...
... have discovered how cells fine-tune their oxygen use to make ... Too little oxygen threatens life by compromising mitochondria that power ... by replacing one protein with an energy-efficient substitute that "is ... begins to run out of gas," says Gregg Semenza, M.D., ...
Cached Biology News:Scientists find genes involved in the battle between Hessian flies and wheat 2Scientists find genes involved in the battle between Hessian flies and wheat 3Navigable nanotransport 2Need oxygen? Cells know how to spend and save 2
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: